patients ($1,042 vs. $1,593, pϭ0.0034). The pharmacy costs were, however, higher in these patients, compared to SOC-initiated patients ($4,358 vs. $3,235, pϽ0.001). In addition, duloxetine-initiated patients were less likely to use any opioids (56% vs. 63%, pϽ0.05) compared with SOC patients not initiated on opioids. CONCLUSIONS: Commercially-insured CLBP patients initiating duloxetine were associated with significantly lower inpatient costs and CLBP-related outpatient costs, but higher pharmacy costs, compared to patients initiating other SOC treatments. Duloxetineinitiated patients were also less likely to use opioids in the post-index year. Studies of interest included: 1) cost studies; 2) economic evaluations; or 3) narrative or systematic reviews related to economic evaluations of biological treatments used for moderate-to-severe CD. Exclusion criteria included the following characteristics: 1) CDrelated cost studies that were narrative or systematic reviews; 2) CD-related cost studies that did not include costs of biologic treatments; 3) studies published only as abstracts; or 4) non-English studies. The primary outcomes of interest included costs associated with biological treatments and cost-effectiveness measures including incremental cost-effectiveness ratios. A threshold value of $50,000/QALY or £30,000/QALY was used to judge treatment cost-effectiveness. RESULTS: Twenty-nine studies were identified, including 12 economic evaluations and 17 cost studies or reviews of economic evaluations. Economic evaluation studies illustrated that infliximab was cost-effective compared with standard care for luminal CD when provided as induction therapy followed by: 1) episodic therapy over 5 or more years, or 2) maintenance therapy over one year. Additionally, adalimumab was found to be more cost-effective than both infliximab and standard care for luminal CD in terms of 1-year maintenance treatment with or without prior induction treatment. Cost studies revealed that infliximab usage reduced overall healthcare resource utilization and cost. Older reviews were inconclusive on the costeffectiveness of biologic treatments used for CD. CONCLUSIONS: Limited evidence suggests that biologic treatments are cost-effective for CD under certain clinical situations. Future studies are recommended to include all indicated biologic treatments to provide a systematic comparison regarding their comparative benefits and costs. [2004][2005][2006][2007][2008]. Pso patients were matched (based on age and gender) to continuously enrolled adult Pso-free patients (i.e., without diagnosis for Pso or psoriatic arthritis). WPL was estimated using workplace absenteeism and short term disability (STD) expenditures available in the MarketScan Health and Productivity Management database. Only patients for whom the employer recorded absenteeism and STD were included in the analysis. WPL, often referred to as total indirect cost, was defined as the sum of absenteeism costs (i.e., hours out of work for medical reasons [sick leave]* hourly wage) and STD costs (number of days on disability * daily wage). Wages were imputed based on the regions of residence using data from the U.S. Bureau of Labor Statistics. Annual incremental costs associated with WPL in Pso patients were stratified by Pso severity (mild or moderate-to-severe) and estimated using generalized linear models. Moderate-to-severe Pso patients were defined as patients who used systemic therapies during the 6-month baseline period; mild Pso patients did not use any systemic therapies during the baseline period. RESULTS: A total of 1137 matched pairs were included. Among Pso patients, 305 (26.8%) had moderate-tosevere Pso. After adjusting for confounding factors (age and gender), no significant cost differences associated with WPL were found when comparing mild Pso to Pso-free patients ($1827 for mild Pso vs. $1770 for Pso-free; differenceϭ $52, pϭ0.825). When compared to Pso-free patients, however, moderate-to-severe Pso patients were associated with significant incremental WPL of $1026 per patientyear ($2781 for moderate-to-severe Pso vs. $1770 for Pso-free; pϭ0.014). CONCLUSIONS: Pso imparts a substantial WPL in patients with moderate-to-severe Pso. 
OBJECTIVES:
To systematically review published literature assessing the economic evidence of biologic treatments indicated for Crohn's disease (CD). METHODS: Published articles between January 1995 and June 2011 were searched in PubMed, EMBASE, ABI/INFORM, Tuft's Cost-Effectiveness Analysis Registry Database, Cochrane National Health Service Economic Evaluation Database, International Pharmaceutical Abstracts, Web of Science, and Google Scholar. Studies of interest included: 1) cost studies; 2) economic evaluations; or 3) narrative or systematic reviews related to economic evaluations of biological treatments used for moderate-to-severe CD. Exclusion criteria included the following characteristics: 1) CDrelated cost studies that were narrative or systematic reviews; 2) CD-related cost studies that did not include costs of biologic treatments; 3) studies published only as abstracts; or 4) non-English studies. The primary outcomes of interest included costs associated with biological treatments and cost-effectiveness measures including incremental cost-effectiveness ratios. A threshold value of $50,000/QALY or £30,000/QALY was used to judge treatment cost-effectiveness. RESULTS: Twenty-nine studies were identified, including 12 economic evaluations and 17 cost studies or reviews of economic evaluations. Economic evaluation studies illustrated that infliximab was cost-effective compared with standard care for luminal CD when provided as induction therapy followed by: 1) episodic therapy over 5 or more years, or 2) maintenance therapy over one year. Additionally, adalimumab was found to be more cost-effective than both infliximab and standard care for luminal CD in terms of 1-year maintenance treatment with or without prior induction treatment. Cost studies revealed that infliximab usage reduced overall healthcare resource utilization and cost. Older reviews were inconclusive on the costeffectiveness of biologic treatments used for CD. CONCLUSIONS: Limited evidence suggests that biologic treatments are cost-effective for CD under certain clinical situations. Future studies are recommended to include all indicated biologic treatments to provide a systematic comparison regarding their comparative benefits and costs. 
PSY17 ECONOMIC BURDEN ASSOCIATED WITH WORKPLACE PRODUCTIVITY LOSSES (WPL) IN PATIENTS WITH PSORIASIS IN A POPULATION IN THE UNITED STATES

OBJECTIVES:
This retrospective study aimed to estimate the economic burden associated with WPL in patients with psoriasis (Pso) in a US based population. METHODS: Continuously enrolled adult patients with Ն2 Pso diagnoses were selected from the MarketScan Claims database (2004) (2005) (2006) (2007) (2008) . Pso patients were matched (based on age and gender) to continuously enrolled adult Pso-free patients (i.e., without diagnosis for Pso or psoriatic arthritis). WPL was estimated using workplace absenteeism and short term disability (STD) expenditures available in the MarketScan Health and Productivity Management database. Only patients for whom the employer recorded absenteeism and STD were included in the analysis. WPL, often referred to as total indirect cost, was defined as the sum of absenteeism costs (i.e., hours out of work for medical reasons [sick leave]* hourly wage) and STD costs (number of days on disability * daily wage). Wages were imputed based on the regions of residence using data from the U.S. Bureau of Labor Statistics. Annual incremental costs associated with WPL in Pso patients were stratified by Pso severity (mild or moderate-to-severe) and estimated using generalized linear models. Moderate-to-severe Pso patients were defined as patients who used systemic therapies during the 6-month baseline period; mild Pso patients did not use any systemic therapies during the baseline period. RESULTS: A total of 1137 matched pairs were included. Among Pso patients, 305 (26.8%) had moderate-tosevere Pso. After adjusting for confounding factors (age and gender), no significant cost differences associated with WPL were found when comparing mild Pso to Pso-free patients ($1827 for mild Pso vs. $1770 for Pso-free; differenceϭ $52, pϭ0.825). When compared to Pso-free patients, however, moderate-to-severe Pso patients were associated with significant incremental WPL of $1026 per patientyear ($2781 for moderate-to-severe Pso vs. $1770 for Pso-free; pϭ0.014). CONCLUSIONS: Pso imparts a substantial WPL in patients with moderate-to-severe Pso. 
PSY18 ECONOMIC BURDEN OF PSORIASIS (PSO) AND OBESITY IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
OBJECTIVES:
To estimate incremental resource use and costs of Pso and obesity in Pso patients. METHODS: Adult Pso patients (Ն2 Pso diagnoses) were selected from a large US claims database (2004) (2005) (2006) (2007) (2008) . Pso patients were matched (based on age and gender) to Pso-free patients (i.e., without Pso or psoriatic arthritis diagnosis).
Obesity was defined based on patients' reported body mass index (BMIՆ30).
Healthcare resource use and costs were assessed over a one-year period. Incidence rate differences and incremental annual total health care costs (USD 2010; measured from a payer perspective) associated with Pso and obesity between Pso and Pso-free patients were estimated using multivariate Poisson regression models and generalized linear regression models, respectively, controlling for age, gender, and Charlson comorbidity index. RESULTS: A total of 1874 matched pairs with reported BMI were selected. Among Pso patients, 34% were obese compared to 28% of the Pso-free controls (pϽ0.01). Compared to non-obese Pso patients, obese Pso patients had on average 7 more urgent care visits (hospitalizations and emergency department visits) per 100 patient-years (p ϭ0.02), and 1.8 more outpatient visits per patient-years (p ϭ0.01). Compared to Pso-free patients, Pso was associated with 5.0 more outpatients visits per patient-years in non-obese patients and 6.3 more outpatients visits per patient-year in obese patients (both p Ͻ0.01). Among Pso patients, obesity presented a $2,729 incremental cost compared to the non-obese Pso patients ($12,670 vs. $9,192; pϽ0.01) . Compared to Pso-free patients, Pso was associated with a $4,735 incremental total health care cost among non-obese patients ($9,192 vs. $4,681; pϽ0.01 ) and a $6,887 incremental cost among obese patients ($12,670 vs. $5,460; pϽ0.01) . The difference ($2152) between $6887 and $4735 was not statistically significant in the final model. CONCLUSIONS: Pso patients have higher prevalence of obesity when compared to Pso-free patients. Both Pso and obesity were associated with significant incremental costs. 
PSY19 BURDEN OF ILLNESS (BOI) OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML)
OBJECTIVES:
Patients with FLT3-mutated AML have poor prognoses due to short survival, high incidence of relapse, and a lack of effective treatment options. The objective of this study was to review AML-related literature and estimate the economic burden of FLT3-mutated AML in the United States. METHODS: A systematic literature review was conducted to identify relevant publications from 2000-2011.
Estimates of the epidemiology of FLT3-mutated AML were calculated from SEER data and US Census projections. An Excel model was developed to estimate the BOI of FLT3-mutated AML. Resource utilization estimates were obtained from the literature and expert opinion. RESULTS: A total of 607 citations were identified and 35 articles abstracted. No direct estimates for the incidence or prevalence of FLT3-mutated AML in the United States were identified in the literature. The prevalence of AML in 2008 was obtained from SEER data (27,813 patients aged Ն20 years). In 2010, it was estimated that 784 adults Ͻ60 years and 1,622 adults Ն60 years were diagnosed with FLT3-mutated AML. The BOI of FLT3-mutated AML in the US was estimated at $251 million in 2010, including $191 million in direct costs and $60 million in lost productivity. For newly diagnosed patients Ͻ60 years, the burden of FLT3-mutated AML was estimated at $90 million in 2010. Inpatient hospitalizations accounted for 36% of direct costs and stem cell transplants for 38%. The cost per A101 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
